Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"JANSSEN NZ LIMITED, JANSSEN NZ LIMITED, Consumer","Daratumumab (in combination with bortezomib, cyclophosphamide and dexamethasone)","AL amyloidosis, 1L","Daratumumab (in combination with bortezomib, cyclophosphamide and dexamethasone) (DarzalexÂ® SC (AL-A))",Options for investment,Hospital,Oncology Agents and Immunosuppressants
